EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)

Inclusion Criteria: * Willing and able to give informed consent and comply with study procedures and follow-up through 1 year. * Plan to undergo an invasive strategy after receiving study drug for 12 to 96 hours. * Able to be randomized into the trial within 12 hours of having symptoms of acute coronary syndrome. * Experiencing symptoms of cardiac ischemia at rest (angina or anginal equivalent) with episode(s) lasting at least 10 minutes and have at least 2 of the following: * 60 years of age or more * Electrocardiogram changes (ECG) * Elevated troponin (protein released in the blood stream in people suffering from acute coronary syndrome) or CK-MB levels * Or have all 3 of the following: * Prior history of cardiovascular disease * Elevated troponin or CK-MB levels * 50-59 years of age Exclusion Criteria: * pregnancy (known or suspected) * renal dialysis within 30 days prior to randomizing in study * other serious illnesses or any condition that the investigator feels would pose a significant hazard to the patient if the investigational therapy was to be initiated * Stroke (hemorrhagic stroke at any time or non-hemorrhagic stroke within previous 7 days), central nervous system damage (such as neoplasm, aneurysm, intracranial surgery), bleeding disorders (including gastrointestinal bleeding), or recent major surgery or major trauma. * History of certain hematologic problems following treatment with heparin or eptifibatide. * Therapy with certain related drugs within a short time before randomization into the trial.